KR900014321A - 신경변성 질환에 유용한 테트라하이드로퀴놀린 유도체 - Google Patents

신경변성 질환에 유용한 테트라하이드로퀴놀린 유도체 Download PDF

Info

Publication number
KR900014321A
KR900014321A KR1019900003022A KR900003022A KR900014321A KR 900014321 A KR900014321 A KR 900014321A KR 1019900003022 A KR1019900003022 A KR 1019900003022A KR 900003022 A KR900003022 A KR 900003022A KR 900014321 A KR900014321 A KR 900014321A
Authority
KR
South Korea
Prior art keywords
dichloro
tetrahydroquinoline
carboxy
benzylcarbonylamino
compound
Prior art date
Application number
KR1019900003022A
Other languages
English (en)
Inventor
베이커 레이몬드
카알링 윌리암.
디. 리슨 폴
디. 스미스 줄리앙
Original Assignee
알란 헤스케스
머크 샤프 앤드 도움 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898905334A external-priority patent/GB8905334D0/en
Priority claimed from GB898926431A external-priority patent/GB8926431D0/en
Application filed by 알란 헤스케스, 머크 샤프 앤드 도움 리미티드 filed Critical 알란 헤스케스
Publication of KR900014321A publication Critical patent/KR900014321A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other Liquid Machine Or Engine Such As Wave Power Use (AREA)
  • Hydrogenated Pyridines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

내용 없음

Description

신경변성 질환에 유용한 테트라하이드로퀴놀린 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 일반식(Ⅰ)의 화합물 또는 이의 염.
    상기식에서, R1은 산성 그룹 또는 생체내에서 산성으로 전환될 수 있는 그룹이고; R2는 수소 또는 탄화수소이며; R3는 수소, 탄화수소 -ORa, -SRa, -NRaRb, -NRaRb, -NRaCO2Rb, -NRaSO2Rb-NR1CXNRaRb, -CO2Ra또는 -CONRaRb이고; R4는 탄화수소, -ORa, -SRa, -NRaRb, -NRaCORb, -NRaCO2Rb, -NRaSO2Rb, -NR1CXNRaRb, -CO2Ra또는 -CONRaRb이거나; R3및 R4는 이들 사이에 있는 탄소 원자와 함께 카보닐(C=O), 티오카보닐(C=S), 이미노(C=N,Ra), 옥시미노(C=N,ORa), 또는 산소, 질소, 황 및 인 중에서 선택된 헤테로원자, 0내지 4개를 함유하는 3-내지 8-원환이며; R5, R6, R7, 및 R8은 독립적으로 수소, 탄화수소, 할로겐, 시아노, 트리플루오로메틸, 니트로, -ORa, SRa, -NRaRb또는 -CO2Ra이고; Ra, Rb, R1는 독립적으로 수소 또는 탄화수소이며, X는 산소, 황 또는 식=N,E의 그룹이고; E는 탄화수소 또는 전자구인성 그룹이며; 단 R2, R5, R6및 R7이 각각 수소이고 R3및 R4가 사이에 있는 탄소 원자와 함께 카보닐인 경우, R1이 카복시 또는 메톡시카보닐이라면, R8은 수소가 아니며, R1이 카복시라면, R8은 하이드록시가 아니고; R2, R3, R5, R6, R7및 R8이 각각 수소인 경우, R1및 R4는 동시에 카복시 또는 에톡시카보닐이 아니다.
  2. 제1항에 있어서, 일반식(ⅡA)의 화합물 및 이의 염.
    상기식에서, R1, R2, R5, R6, R7및 R8은 제1항에서 정의한 바와같고; R14는 탄화수소, -NRaRb,-NRaCORb, -NRaCO2Rb, -CO2Ra또는 -CONRaRb(여기서 Ra및 Rb는 제1항에서 정의한 바와같다)이다.
  3. 제1항에 있어서, 일반식(ⅡB)의 화합물 및 이의염.
    상기식에서, R1, R2, R5, R6, R7및 R8은 제1항에서 정의한 바와같고; R24는 -NRaRb, -NRaCO2Rb, -NRaSO2Rb, -CO2Ra또는 -CONRaRb(여기서 Ra및 Rb는 제1항에서 정의한 바와같다)이다.
  4. 제1항에 있어서, 일반식(ⅡC)의 화합물 및 이의염.
    상기식에서, R1, R2, R5, R6, R7및 R8은 제1항에서 정의한 바와같고; -Ra및 Rb는 독립적으로, 수소, C1-6알킬, C2-6알케닐, C3-7사이클로알킬, C3-7사이클로알킬(C1-6)알킬, 아릴, 아릴(C1-6)알킬, C3-7헤테로사이클로알킬, C3-7헤테로사이클로알킬(C1-6)알킬, 헤테로아릴 또는 헤테로아릴(C1-6)알킬이며, 이들 그룹은 어느 것이나 임의로 치환될 수 있다.
  5. 제1항에 있어서, 일반식(ⅡD)의 화합물 및 이의염.
    상기식에서, R1, R2, R5, R6, R7및 R8은 제1항에서 정의한 바와같고; -Ra및 R1는 독립적으로, 수소, C1-6알킬또는 아릴이며; Rb는 C3-7사이클로알킬, 아릴 또는 아릴(C1-6)알킬이고, 이들 그룹은 어느것이나 임의로 치환될수 있으며; X는 산소 또는 황이다.
  6. 제1항에 있어서, 일반식(ⅡE)의 화합물 및 이의염.
    상기식에서, R1, R2, R5, R6, R7및 R8은 제1항에서 정의한 바와같고; Q는 산소, 질소, 황 및 인 중에서 선택된 헤테로원자 0내지 4개를 함유하는 3-내지 8-원 환의 잔기이다.
  7. 제1항에 있어서, 2-카복시-5,7-디클로로-4-옥소-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디메틸-4-옥소-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-4-옥소-3,5,7-트리메틸-1,2,3,4-테트라하이드로퀴놀린; 4-5-부톡시카보닐아미노-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린; 4-아미노-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린; 4-벤조일아미노-2카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린; 4-아세틸아미노-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;5,7-디클로로-4-(1,3-디옥솔란-2-일)-2-(2-하이드록시에톡시카보닐)-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디클로로-4-(2,4-이미다졸리딘디온-3-일)-1,2,3,4-테트라하이드로퀴놀린; 2,4-디코복시-5,7-디클로로-1,2,3,4-테트라 하이드로퀴놀린; 2-카복시-5,7-디클로로-4-에톡시카보닐-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디클로로-4-(3,5-디클로로페닐 아미노)-4-에톡시카보닐-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디클로로-4-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린; 4-벤질옥시카보닐-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린: 2-카복시-5,7-디클로로-4-(3-메틸-1,2,3,4-옥사디아졸-5-일)-1,2,3,4-테트라하이드로퀴놀린; 4-아미노카보닐-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디메틸-4-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-4-메톡시카보닐-5,6,7-트리클로로-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-7-클로로-5-요오도-4-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-7-클로로-4-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5-클로로-4-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디브로모-4-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디클로로-4-메탄설포닐아미노-1,2,3,4-테트라하이드로퀴놀린;오-카복시-5,7-디클로로-4-사이클로헥실카보닐아미노-1,2,3,4-테트라하이드로퀴놀린; 4-벤질카보닐아미노-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디클로로-4-(1-나프틸카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-4-(2-클로로페닐카보닐아미노)-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-4-(4-클로로페닐카보닐아미노)-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디클로로-4-(4-피리딜카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디클로로-4-[2-(2-아미노펜에틸)]-카보닐아미노-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디클로로-4n-프로필카보닐아미노-1,2,3,4-테트리하이드로퀴놀린; 2-카복시-5,7-디클로로-4-페닐아미노카보닐아미노-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-4-(4-클로로페닐카보닐아미노)-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디클로로-4-(4-메톡시페닐카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린; 4-벤질아미노카보닐미노-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디클로로-4-(2-메톡시벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2-메틸벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린; 2-카복시-5,7-디클로로-4-(α-메톡시벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2-니트로벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2-니트로페닐아미노 카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2-메톡시페닐아미노카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2-메틸페닐아미노카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-(2-클로로페닐아미노카보닐아미노)-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-(4′-비페닐카보닐아미노)-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-이소프로필카보닐아미노-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-(2-클로로페닐카보닐아미노)-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(1-나프틸카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2-나프틸카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2-푸릴카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2-메틸페닐카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2-펜에틸카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2-페닐에테닐카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2-티에닐메틸카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-(3-클로로페닐카보닐아미노)-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(3-페닐프로필카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(9-플루오레닐카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-사이클로헥실메틸카보닐아미노-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-(2-클로로벤질카보닐아미노)-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-(3-클로로벤질카보닐아미노)-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-(4-클로로벤질카보닐아미노)-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(4-메틸벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(4-메톡시벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(4-니트로벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-(3-시아노페닐카보닐아미노)-5,7-디클로로-1,2,3,4-테트라히이드로퀴놀린;2-카복시-4-(4-클로로페닐아미노카보닐아미노)-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(4-메틸페닐아미노카보닐-아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(4-메톡시페닐아미노카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(4-니트로페닐아미노카보닐-아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(4-요오도페닐아미노카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-[페닐아미노카보닐(N-메틸)아미노]-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-[(N-메틸-N-페닐)아미노카보닐아미노]-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2,3-디하이드로인돌-1-일카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-[2-(카복시에틸)카보닐아미노]-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-[3-(아미노메틸)페닐카보닐아미노]-2-카복시-5,7-디클로로-1,2,3, 벤진카보닐아미노/벤질카보닐아미노4-테트라하이드로퀴놀린;4-[3-(아미노메틸)페닐카보닐아미노]-5,7-디클로로-2-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린;4-[4-(아미노메틸)페닐카보닐아미노]-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-[4-(아미노메틸)페닐카보닐아미노]-5,7-디클로로-2-메틸시카보닐-1,2,3,4-테트라하이드로퀴놀린;4-[4-(2-아미노메틸)페닐카보닐아미노]-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-[4-(2-아미노메틸)페닐카보닐아미노]-5,7-디클로로-2-메톡사카보닐-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(3-매틸벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(3-니트로벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(3-메톡시벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(1-나프틸메틸카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2-나프틸메틸카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(3-티에닐메틸카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(2,6-디클로로벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-페닐아미노티오카보닐아미노-1,2,3,4-테트라하이드로퀴놀린;4-벤질옥시카보닐아미노-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(3-메톡시페닐아미노카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(3-메틸페닐아미노카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-(3-클로로페닐아미노카보닐아미노)-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(3-니트로페닐아미노카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;4-(3-아미노프로필)카보닐아미노-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-(2-아미노에틸)카보닐아미노-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-(4-아미노부틸)카보닐아미노-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(4-피페리딜메틸카보닐-아미노)-1,2,3,4-테트라하이드로퀴놀린;4-[4-(아미노메틸)벤질카보닐아미노]-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-[4-(아미노메틸)벤진카보닐아미노]-5,7-디클로로-2-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린;4-[4-(2-아미노에틸)벤진카보닐아미노]-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-[4-(2-아미노에틸)벤진카보닐아미노]-5,7-디크로로-2-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-[4-N-메틸아미노메틸)-벤질카보닐아미노]-1,2,3,4-테트라하이드로퀴놀린;5,7-디클로로-2-메톡시카보닐-4-[4-(N-메틸아미노-메틸)벤질카보닐아미노]-1,2,3,4-테트라하이드로퀴놀린;5,7-디클로로-4-[4-(N,N-디메틸아미노메틸)벤질카보닐아미노]-2-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-[4-(N,N-디메틸아미노메틸)-벤질카보닐아미노]-1,2,3,4-테트라하이드로퀴놀린;4-[4-(3-아미노프로프-2-이닐)벤질카보닐아미노]-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-[4-(3-아미노프로프-2-이닐)벤질카보닐아미노]-5,7-디클로로-2-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린;4-[4-(3-아미노프로필)벤질카보닐아미노]-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-[4-(3-아미노프로필)벤질카보닐아미노]-5,7-디클로로-2-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린;4-[4-(3-아미노부트-2-이닐)벤질카보닐아미노]-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-[4-(4-아미노부트-2-이닐)벤질카보닐아미노]-5,7-디클로로-2-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린;4-[-(4-아미노부틸)벤질카보닐아미노]-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-[4-(4-아미노부틸)벤질카보닐아미노]-5,7-디클로로-2-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린;4-[3-(아미노에틸)벤질카보닐아미노]-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-[3-(아미노메틸)벤질카보닐아미노]-5,7-디클로로-2-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린;4-[2-(아미노메틸)벤질카보닐아미노]-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-[2-(아미노메틸)벤질카보닐아미노]-5,7-디클로로-2-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린;4-[2-(4-아미노메틸)페닐)에틸카보닐아미노]-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-[2-(4-아미노메틸)페닐)에틸카보닐아미노]-5,7-디클로로-2-메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린;4-(4-아미노벤질카보닐아미노)-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(1,2,3,4-테트라하이드로이소퀴놀-3-일카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-(2-카복시페닐카보닐아미노)-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-(4-클로로-3-니트로벤질카보닐아미노)-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(4-하이드록시-3-니트로벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(디페닐메틸카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(1-페닐에틸)카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;4-(4-아세틸벤질카보닐아미노)-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-페녹시메틸카보닐아미노-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(4-에틸벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(4-하이드록시벤질카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;4-(4-아세트아미노벤질카보닐아미노)-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(1-나프틸아미노카보닐아미노)-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-사이클로헥실아미노카보닐아미노-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-[N-메틸-N(4-메틸페닐)-아미노]카보닐아미노-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(N,N-디페닐아미노)카보닐아미노-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(4-에틸페닐)아미노카보닐아미노-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-(N-에틸-N-페닐)아미노카보닐아미노-1,2,3,4-테트라하이드로퀴놀린;4-벤질아미노-2-카복시-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-페닐아미노카보닐메틸)-아미노-1,2,3,4-테트라하이드로퀴놀린;4-벤질카보닐아미노-2-(t-부틸카보닐옥시)메톡시-카보닐-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;4-벤질카보닐아미노-5,7-디클로로-2-(메틸아미노-카보닐)메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린;4-벤질카보닐아미노-5,7-디클로로-2-[2-(N,N-디메틸아미노)에틸아미노카보닐]메톡시카보닐-1,2,3,4-테트라하이드로퀴놀린;4-벤질카보닐아미노-5,7-디클로로-2-[2-(N,N-디메틸아미노)에톡시카보닐]-1,2,3,4-테트라하이드로퀴놀린;4-벤질카보닐아미노-5,7-디클로로-2-[3-(N,N-디메틸아미노)프로폭시카보닐]-1,2,3,4-테트라하이드로퀴놀린;4-벤질카보닐아미노-5,7-디클로로-2-[2-(N,N-디메틸아미노)에틸아미노카보닐]-1,2,3,4-테트라하이드로퀴놀린;5,7-디클로로-2-[2-(N,N-디메틸아미노)에틸아미노카보닐]-4-페닐아미노카보닐아미노-1,2,3,4-테트라하이드로퀴놀린;4-[4-(아미노메틸)벤질카보닐아미노]-5,7-디클로로-2-(메틸아미노카보닐)메톡시카보닐-1,2,3,4-테트라하이로퀴놀린;4-[4-(아미노메틸)벤질카보닐아미노]-5,7-디클로로-2-헥실옥시카보닐-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-메톡시카보닐메틸-1,2,3,4-테트라하이드로퀴놀린;2-카복시-4-카복시메틸-5,7-디클로로-1,2,3,4-테트라하이드로퀴놀린;2-카복시-5,7-디클로로-4-페닐아미노카보닐메틸-1,2,3,4-테트라하이드로퀴놀린중에서 선택된 화합물 및 이의 염.
  8. 약제학적으로 허용되는 담체와 함께 제1항 내지 7항중 어느 한항에 청구된 바와같은 화합물을 함유하는 약제학적 조성물.
  9. 치료제로 사용하기 위한, 제1항 내지 제7항중 어느 한항에 청구된 바와같은 화합물.
  10. 신경변성 질환의 치료 및/또는 예방용 약제를 제조하기 위한, 제1항 내지 7항중 어느 한항에 청구된 바와같은 화합물의 용도.
  11. (A)일반식(Ⅳ)의 퀴놀린 유도체를 환원시켜 R3가 수소인 화합물을 제조하거나, (B)일반식 A-CORb, A-CO2Rb또는 A-SO2Rb(여기서, A 및 Rb는 하기 정의한 바와같다)의 화합물을 각각 일반식(Ⅴ)의 화합물과 반응시켜 R3가 수소이고 R4가 식-NRaCORb, -NRaCO2Rb또는 -NRaSO2Rb(여기서, Ra및 Rb는 하기 정의한 바와같다)그룹인 화합물을 제조하거나; (C)일반식(Ⅵ)의 화합물을 환원시켜 R3가 수소이고 R4가 -NH2인 화합물을 제조하거나; (D)일반식(Ⅶ)의 화합물을 일반식 H2N, ORa(여기서, Ra는 하기 정의한 바와같다)의 하이드록실아민유도체 또는 이의 염으로 처리하여 R3및 R4가 이들 사이에 있는 탄소원자와 함게 옥시미노(C=N,ORa)그룹을 나타내는 화합물을 제조하거나; (E)일반식(Ⅶ)의 화합물을 환원제의 존재하에서 일반식 RaNH2(여기서, Ra는 하기 정의한 바와같다)의 아민으로 처리하여 R3가 수소이고 R4가 -NH2인 화합물을 제조하거나; (F)일반식(Ⅷ)의 카복실 산의 반응성 유도체를 폐환반응시킨 다음 아미노-보호 그룹 R11을 제거하여 R3을 R4가 이들 사이에 있는 탄소원자와 함께 카보닐(C=0)그룹을 나타내는 화합물을 제조하거나; (G)일반식(X)의 화합물, 또는 이의 보호된 유도체를 일반식(ⅩⅠ)의 화합물, 또는 이의 보호된 유도체와 반응시킨 다음, 경우에 따라, 보호 구룹을 제거하거나; (H)일반식(ⅩⅡ)의 카복실 산의 반응성 유도체를 일반식(ⅩⅢ)의 화합물, 또는 이의 염과 반응시키거나; (Ⅰ)일반식(ⅤⅡ)의 화합물을 탄산 암모늄의 존재하에서 나트륨 시아나이드로 처리하거나; (J)일반식(ⅤⅡ)의 화합물을 에틸렌 글리콜로 처리함을 특징으로 하여, 제1항에 청구된 바와같은 화합물을 제조하는 방법.
    상기식에서, R1, R2, R4, R5, R6, R7, R8, Ra, Rb는 제1항에서 정의한 바와같고, R11은 아미노-보호 그룹이며, A는 이탈 그룹이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900003022A 1989-03-08 1990-03-08 신경변성 질환에 유용한 테트라하이드로퀴놀린 유도체 KR900014321A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8905334.2 1989-03-08
GB898905334A GB8905334D0 (en) 1989-03-08 1989-03-08 Therapeutic agents
GB898926431A GB8926431D0 (en) 1989-11-22 1989-11-22 Therapeutic agents
GB8926431.1 1989-11-22

Publications (1)

Publication Number Publication Date
KR900014321A true KR900014321A (ko) 1990-10-23

Family

ID=26295073

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900003022A KR900014321A (ko) 1989-03-08 1990-03-08 신경변성 질환에 유용한 테트라하이드로퀴놀린 유도체

Country Status (11)

Country Link
EP (1) EP0386839B1 (ko)
JP (1) JPH0334969A (ko)
KR (1) KR900014321A (ko)
AT (1) ATE147732T1 (ko)
AU (1) AU5114490A (ko)
CA (1) CA2011686A1 (ko)
DE (1) DE69029668T2 (ko)
FI (1) FI901148A0 (ko)
IL (1) IL93610A0 (ko)
NO (1) NO901082L (ko)
PT (1) PT93362A (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268378A (en) * 1990-05-31 1993-12-07 Merck Sharp & Dohme, Limited Dioxo-tetrahydroquinoline derivatives
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
EP0573562B1 (en) * 1991-02-27 1996-04-24 Merrell Pharmaceuticals Inc. Dihydroquinoline NMDA antagonists
US5606063A (en) * 1991-02-27 1997-02-25 Merrell Pharmaceuticals Inc. NMDA antagonists
GB9109007D0 (en) * 1991-04-26 1991-06-12 Merck Sharp & Dohme Therapeutic method
FR2683818B1 (fr) * 1991-11-14 1993-12-31 Adir Cie Nouveaux derives de 3-sulfonylamino-2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
CA2232509A1 (en) * 1995-09-29 1997-04-10 Glaxo Wellcome Spa Tetrahydroquinolines as nmda antagonists
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
DE19705133A1 (de) * 1997-02-11 1998-08-13 Hoechst Ag Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
EP1607389A1 (en) * 1999-09-10 2005-12-21 Pfizer Products Inc. 4-protected-amino-2-substituted-1,2,3,4-tetrahydroquinolines as intermediates for CETP inhibitors
DE10000311A1 (de) 2000-01-05 2001-07-12 Gruenenthal Gmbh Aminomethyl-Phonyl-Cyclohexanonderivate
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
CA2416454A1 (en) * 2000-12-07 2003-01-14 Japan Science And Technology Corporation Intermediates for synthesis of vinblastine and its congeners, and a method for synthesis of the intermediates
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
DE10137488A1 (de) * 2001-08-03 2003-02-20 Gruenenthal Gmbh Salze substituierter 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137487A1 (de) 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
JP4932730B2 (ja) * 2004-11-24 2012-05-16 アボット・ラボラトリーズ バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH23848A (en) * 1985-05-24 1989-11-23 Ciba Geigy Ag Certain phosphonic acids and derivatives
GB8719102D0 (en) * 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
EP0386839A3 (en) 1991-10-23
DE69029668T2 (de) 1997-08-07
JPH0334969A (ja) 1991-02-14
ATE147732T1 (de) 1997-02-15
NO901082D0 (no) 1990-03-07
CA2011686A1 (en) 1990-09-08
IL93610A0 (en) 1990-12-23
EP0386839B1 (en) 1997-01-15
FI901148A0 (fi) 1990-03-07
PT93362A (pt) 1990-11-07
DE69029668D1 (de) 1997-02-27
EP0386839A2 (en) 1990-09-12
AU5114490A (en) 1990-09-13
NO901082L (no) 1990-09-10

Similar Documents

Publication Publication Date Title
KR900014321A (ko) 신경변성 질환에 유용한 테트라하이드로퀴놀린 유도체
AU754716B2 (en) Amide derivatives and nociceptin antagonists
JP2005521698A (ja) 新規な三環式化合物
KR860004048A (ko) 7-아미노-1-시클로프로필-6,8-디플루오로-1,4-디히드로-4-옥소-퀴놀린-3-카르복실산의 제조방법
NO904134D0 (no) Fremgangsmaate for fremstilling av pyrazolderivater.
KR900007829A (ko) 2(1h)-퀴놀리는 화합물, 이의 제법, 및 이를 함유하는 약제학적 조성물
SE9301241L (sv) Indolderivat
KR20010085854A (ko) 단백질 티로신 키나제 억제제로서 치환 3-시아노퀴놀린
RU98110572A (ru) Бензоксазиновые антимикробные средства
DE69015239D1 (de) Chinolinon-Derivate, Verfahren zu ihrer Herstellung und diese Derivate enthaltende antibakteriell wirkende Mittel.
DE68920797T2 (de) Herzmittel.
IE63429B1 (en) 4-amino quinolines and naphthyridines process for their preparation and their use as medicines
NO900542D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzokondenserte n-holdige heterocykliske derivater.
PE20000325A1 (es) Derivados de 2-ariletil-(piperidin-4-ilmetil)amina
US3897432A (en) Substituted benzimidazole derivatives
KR930701415A (ko) 약학적으로 활성인 벤조퀴나졸린 화합물
KR930002372A (ko) 약리학적으로 활성인 히드라진 유도체 및 이의 제조방법
ES2132284T3 (es) Derivados de carbamato de 2-(piperidin-4-il, piridin-4-il y tetrahidropiridin-4-il)-benzofurano-7, su preparacion y su uso como inhibidores de acetilcolinesterasa.
ATE88344T1 (de) Zur behandlung von neurodegenerativen erkrankungen verwendbare kynurensaeurederivate.
KR920019746A (ko) 신규한 시클로헥실벤즈아미드 유도체, 그의 제조방법 및 약제로서의 용도
KR890001957A (ko) N-아미노부틸-n-페닐아릴아미드 유도체, 그의 제법 및 치료에의 응용
KR910002854A (ko) 벤즈아진 화합물 및 그의 의약 용도
US4209519A (en) Anti-leishmanial lepidine derivatives
RU2077532C1 (ru) Производные хинолина или их соли, способы их получения, твердая фармацевтическая композиция
KR910014368A (ko) 퀴나졸린 유도체 및 이의 제조방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid